Results 251 to 260 of about 98,309 (302)

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study. [PDF]

Hemasphere
Luminari S, Jiménez-Ubieto A, Chong G, Tucker D, Ambati S, Lin C, Mohamed H, Brouwer-Visser J, Otele CA, Antico G, Villasboas JC.   +10 more
europepmc   +1 more source

CD20 targeting and beyond

, 2010
openaire   +1 more source

Immunotherapy with anti-CD20 compounds

Seminars in Cancer Biology, 2003
The B-cell surface antigen CD20 is currently the prime target for near-selective treatment of mature B-cell malignancies and a range of reactive B-cell associated disorders (including virus-associated lymphoproliferation or autoimmune conditions). CD20 is strongly and homogeneously expressed on the majority of mature B-cell neoplasms except chronic ...
von Schilling, C, Christoph von Schilling   +1 more
openaire   +3 more sources

CD20 Inhibitors: Rituximab

, 2015
The CD20 inhibitors are protein constructs which bind and inactivate CD20. They are members of a group of drugs active in rheumatoid arthritis known as biological disease-modifying antirheumatic drugs (bDMARDs). They are not included in the group slow-acting antirheumatic drugs (SAARDs) because they are considered to have more specific actions and ...
Pile, Kevin (R17082), Graham, Garry G., Mahler, Stephen M.   +2 more
openaire   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Engineering CD20 CARs with a Twist

Cancer Immunology Research, 2023
CD20 is highly expressed in several types of B-cell lymphoma and is an intuitive target for chimeric antigen receptor (CAR) T-cell therapy. However, with conventional approaches, it has been challenging to provide CD20 CAR designs that confer efficacy in preclinical models and in clinical trials.
Lukas Scheller, Michael Hudecek
openaire   +2 more sources

FMC7 is an epitope of CD20

Blood, 2008
To the editor: The FMC7 antibody, originally described in 1981,[1][1] detects an antigen expressed on mature human B cells and is used in immunophenotypic analysis and differential diagnosis of lymphomas and leukemias. The identity of the FMC7 antigen was unclear for many years.
Julie P, Deans, Maria J, Polyak
openaire   +2 more sources